

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Immunotherapy: Combinations (C5)

March 23-27, 2018 • Fairmont The Queen Elizabeth • Montreal, Québec, Canada

Scientific Organizers: Chris R. Boshoff, Lieping Chen and Lisa Coussens

Supported by the Directors' Fund

Abstract & Scholarship Deadline: / Abstract Deadline: / Discounted Registration Deadline:

FRIDAY, MARCH 23

Arrival and Registration

SATURDAY, MARCH 24

Welcome and Keynote Address

Wendy S. Garrett[†], Harvard School of Public Health, USA
Cancer, Immunity and the Microbiome

Rational Immunotherapy Combinations: Preclinical Models as Predictive or Responses

Lieping Chen, Yale University, USA
Design of Combination Therapy Based Adaptive Resistance Mechanisms in Tumor Microenvironment

Michele W. Teng[†], QIMR Berghofer Medical Research Institute, Australia
Improved Mouse Models to Assess Tumor Immunity and irAEs after Combination Cancer Immunotherapies

Speaker to be Announced
Industry Talk

Short Talk(s) Chosen from Abstracts

Workshop: Biomarkers and Patient Selection Strategies for Immunotherapy Combinations

Short Talks Chosen from Abstracts

Incorporating Checkpoint Inhibitors into SOC Chemo- and Radiotherapy Regimens

Jedd D. Wolchok[†], Memorial Sloan-Kettering Cancer Center, USA
Combination Treatment with SOC Checkpoint Inhibitors

Andy Minn[†], University of Pennsylvania, USA
Talk Title to be Announced

Speaker to be Announced
Combination Treatment with SOC Checkpoint Inhibitors

Short Talk Chosen from Abstracts

Poster Session 1

SUNDAY, MARCH 25

Combining Immunotherapy with Tyrosine Kinase and Other Signaling Pathway Inhibitors

Lisa M. Coussens, Oregon Health & Science University, USA
Talk Title to be Announced

Judith A. Varner[†], University of California, San Diego, USA
Targeting PI3Kgamma

Chris Boshoff, Pfizer Inc., USA
Combining Checkpoint Inhibitors with Targeted Therapies

Speaker to be Announced

Short Talk(s) Chosen from Abstracts

Sequencing vs. Combinations: Insights from Biomarker and Preclinical Studies

Sergio A. Quezada[†], University College London, UK
Preclinical Models Predicting Rational Sequencing

Robert H. Vonderheide[†], University of Pennsylvania School of Medicine, USA

Preclinical Models Predicting AEs and Efficacy by Sequencing Combinations

Bernard A. Fox[†], Oregon Health & Science University, USA
Sequencing Checkpoint Therapies

Short Talk Chosen from Abstracts

Poster Session 2

MONDAY, MARCH 26

Immunotherapy Combinations: Preventing and Managing Resistance to Checkpoint Inhibition and T Cell Exhaustion

Peter S. Hammerman[†], Dana-Farber Cancer Institute, USA
Adaptive Resistance to Therapeutic PD-1 Blockade

Antoni Ribas[†], University of California, Los Angeles, USA
Rational Combinations to Prevent or Manage Resistance

Philip D. Greenberg[†], University of Washington, USA
T Cell Exhaustion: Cancer vs. Chronic Infection

Speaker to be Announced
Industry Talk

Short Talk(s) Chosen from Abstracts

Overcoming T Cell Exclusion and an Immune Privilege Microenvironment with Combination Approaches

Douglas T. Fearon[†], Cold Spring Harbor Laboratory, USA
T Cell Exclusion and the Tumor Microenvironment

Johanna A. Joyce[†], University of Lausanne, Switzerland
Acquired Resistance to CSF-1R and other Immunotherapies

Speaker to be Announced

Short Talk Chosen from Abstracts

Poster Session 3

TUESDAY, MARCH 27

Vaccines, Oncolytic Viruses and Cellular Therapies: Towards Combinations

Stephen H. Thorne[†], University of Pittsburgh, USA
Oncolytic Viruses to Sensitize Resistant Tumors to Immunotherapy

Jeffrey Weber[†], NYU Langone Medical Center, USA
Intralesional Therapies Plus Systemic Immunotherapy

Martin Pule[†], University College London, UK
Integrating CART Therapies into SOC

Sunil R. Hingorani[†], Fred Hutchinson Cancer Research Center, USA
Engineered T Cells for Cancer Therapy: From Mouse Models to Clinical Trials

Short Talk(s) Chosen from Abstracts

CTLA-4: Novel Molecules and Approaches to Combinations

Padmanee Sharma[†], University of Texas MD Anderson Cancer Center, USA

CTLA4/PD1 Combinations: Mechanisms of Interactions

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Cancer Immunotherapy: Combinations (C5)

March 23-27, 2018 • Fairmont The Queen Elizabeth • Montreal, Québec, Canada

Scientific Organizers: Chris R. Boshoff, Lieping Chen and Lisa Coussens

Supported by the Directors' Fund

Abstract & Scholarship Deadline: / Abstract Deadline: / Discounted Registration Deadline:

Mario Sznol[†], Yale School of Medicine, USA

CTLA4 Combinations

Speaker to be Announced

Industry Talk

Meeting Wrap-Up: Outcomes and Future Directions (Organizers)

WEDNESDAY, MARCH 28

Departure